Previous Close | 145.40 |
Open | 145.70 |
Bid | 146.00 x 30000 |
Ask | 146.40 x 30000 |
Day's Range | 145.70 - 146.00 |
52 Week Range | 135.00 - 160.40 |
Volume | |
Avg. Volume | 821 |
Market Cap | 352.869B |
Beta (5Y Monthly) | 0.53 |
PE Ratio (TTM) | 30.42 |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | 4.39 (3.02%) |
Ex-Dividend Date | Feb 16, 2024 |
1y Target Est | N/A |
Subscribe to Yahoo Finance Plus to view Fair Value for JNJ.F
ART26.12 Preclinical Dermatology Research Presented to the Immuno-dermatology Leadership Team at Johnson & JohnsonSOLANA BEACH, Calif., March 12, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today announced its selection as a finalist in Johnson & Johnson’s (“J&J’s”; NYSE: JNJ) Innovation Challenge. Thi
NEW BRUNSWICK, N.J., March 11, 2024--Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, April 16th to review first-quarter results. Joaquin Duato, Chairman and Chief Executive Officer, Joseph J. Wolk, Executive Vice President and Chief Financial Officer and Jessica Moore, Vice President, Investor Relations will host the call. The question and answer portion of the call will also include additional members of Johnson & Johnson’s executi
NEW BRUNSWICK, N.J., March 07, 2024--Johnson & Johnson (NYSE: JNJ) announced today it has successfully completed the acquisition of Ambrx Biopharma, Inc., a clinical-stage biopharmaceutical company with a proprietary synthetic biology technology platform to design and develop next-generation antibody drug conjugates (ADCs), in an all-cash merger transaction for a total equity value of approximately $2.0 billion, or $1.9 billion net of estimated cash acquired, as announced on January 8, 2024. The